2. Anti-infection Cell Cycle/DNA Damage Immunology/Inflammation Apoptosis
  3. Bacterial DNA/RNA Synthesis Nuclear Factor of activated T Cells (NFAT) Apoptosis
  4. Usnic acid

Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Usnic acid

Usnic acid 화학구조

CAS No. : 125-46-2

사이즈 가격 재고 수량
무료 샘플 (0.1 - 0.2 mg)   지금 신청하기  
100 mg 해외재고보유
500 mg 해외재고보유
1 g   견적 받기  
5 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 2 publication(s) in Google Scholar

Other Forms of Usnic acid:

Usnic acid Related Antibodies

Top Publications Citing Use of Products

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase[1][2][3][4].

Cellular Effect
Cell Line Type Value Description References
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
In Vitro

Usnic acid (0-40 μg/mL, 0-150 min) inhibits the growth of B. subtilis, S. aureus and V. harveyi[1].
Usnic acid (0.5/1 μg/mL, 15-150 min) inhibits the incorporation rate of DNA, RNA and protein synthesis macromolecular precursors thymidine, uridine and leucine in B. subtilis and S. aureus[1].
Usnic acid (25-100 μM, 24-48 h) inhibits the viability and clonogenicity of A549 cells. It also induces G0/G1 cell cycle arrest, mitochondrial membrane depolarization and apoptosis of A549 cells[2].
Usnic acid (0.3-3 μM, 4 d) inhibits the differentiation of bone marrow-derived macrophages (BMM) into mature osteoclasts in a dose-dependent manner[4].
Usnic acid (3 μM, 0-3 d) inhibits the transcriptional and translational expression of RANKL on NFATc1 in BMMs[4].
Usnic acid (3 μM, 5-30 min) inhibits RANKL-induced activities of MAP kinases p38, ERK and JNK in BMMs[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Usnic acid Related Antibodies

Cell Viability Assay[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24/48 h
Result: Inhibited cell proliferation (35-48%/59-72%).

Cell Proliferation Assay[2]

Cell Line: A549 cells
Concentration: 1, 5, 10 μM
Incubation Time: 7 days
Result: Inhibited cell colony formation (8, 23, 85%).

Cell Cycle Analysis[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24/48 h
Result: Induced cell cycle arrest at G0/G1 (77%, 81% and 80%; 87%, 85%, and 82%).
Down-regulated CDK4, CDK-6 and cyclin D1 protein levels.
Up-regulated p21/Cip1 protein and cleaved-PARP levels.

Apoptosis Analysis[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 48 h
Result: Increased the number of apoptotic cells (6%, 10% and 11%).

RT-PCR[4]

Cell Line: BMMs
Concentration: Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) and M-CSF (30 ng/mL) stimulation
Incubation Time: 0, 1, 2, 3 d
Result: Down-regulated the gene expression levels of TRAP, DC-STAMP, and cathepsin K.

Western Blot Analysis[4]

Cell Line: BMMs
Concentration: Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) stimulation
Incubation Time: 5, 15, 30 min
Result: Down-regulated the protein expression levels of p38, ERK and JNK.
In Vivo

Usnic acid (25-200 mg/kg, p.o., once) can inhibit Indomethacin (HY-14397)-induced gastric injury in rats (80.2-96.4%)[3].
Usnic acid (1 μg/g, i.p., every day for up to 8 days) inhibited osteoclastic bone resorption in the lipopolysaccharide (LPS) bone erosion model [4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Indomethacin-induced gastric damage model (male, Albino-Wistar rats, weighing 180-190 g; Indomethacin 25 mg/kg body weight orally.)[3]
Dosage: 25, 50, 100 and 200 mg/kg
Administration: Oral gavage (p.o.), once
Result: Reduced gastric damage in rats (80.2-96.4%).
Increased SOD, GPx, GSH and cNOS levels.
Reduced CAT, GR, LPO, iNOS and MPx levels.
Animal Model: LPS-induced mouse bone erosion model (five-week-old male ICR mice, 5 µg/µL LPS was injected intraperitoneally on days 1 and 4)[4]
Dosage: 1 μg/g
Administration: Intraperitoneal injection (i.p.), every day for up to 8 days
Result: Increased BMD and BV/TV.
Reduced BS/TV and Tb.Sp.
분자량

344.32

화학식

C18H16O7
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=C(C1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O
Structure Classification
Initial Source
선적

Room temperature in continental US; may vary elsewhere.
보관
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
용액&용해도
In Vitro: 

DMSO : 3.33 mg/mL (9.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9043 mL 14.5214 mL 29.0428 mL
5 mM 0.5809 mL 2.9043 mL 5.8085 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
순도&문서

Purity: 98.90%

SDS (393 KB)

COA (259 KB) HNMR (251 KB) RP-HPLC (261 KB) LCMS (97 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9043 mL 14.5214 mL 29.0428 mL 72.6069 mL
5 mM 0.5809 mL 2.9043 mL 5.8086 mL 14.5214 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Usnic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Usnic acid125-46-2BacterialDNA/RNA SynthesisNuclear Factor of activated T Cells (NFAT)ApoptosisAntibacterialAnticancerB. subtilisS. aureusA549 cellsBMMsIndomethacin-induced gastric damage modelLPS-induced mouse bone erosion modelInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Usnic acid
Cat. No.:
HY-N0656
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.